ERBB2 and breast cancer: Ristimaki et al (2002) found a higher COX-2 expression in HER-2-expressing breast cancer; the present study confirmed this association. Furthermore, dual drug blockade of COX-2 and HER-2 in cancer cell lines expressing both oncogenes has been shown to reduce cell growth more effectively than the inhibition by one of the agents alone (Mann et al, 2001).